We believe that a major strength of Stanford University in this application is its prior interest in treating chronic viral infections which has led to expertise in areas such as virology, viral immunology and pharmacology as well as extensive clinical trials experience. Therefore, it is expected our group can continue to generate new relevant technology, be involved in ACTG core committees in Primary Infection, Pharmacology, Site and Data Management, Protocol Evaluation, Virology and Immunology and thereby produce innovative Phase I and Phase II efforts with new agents as well as be involved in DNA oriented Phase III trials. The first five years of funding utilized the available infected populations in our area particularly in collaboration with Kaiser Foundation Hospital in San Francisco. Now, we recognize that there is a need to study more indigent patients and a new collaboration with a pre-existing clinical research funding consortium will allow us to develop satellite units at Santa Clara and San Mateo County Hospitals. This will increase minority and female involvement and bring more IV drug users and people of color into our program. The Virology Laboratory research is central and unique in performing both a variety of cultures, viral antigen testing and quantitative PCR for viral RNA and DNA methods useful for measuring virus load in vivo. Drug sensitivity tests are being pursued in our current Viral Lab as well for monitoring combination versus monotherapy studies. In addition to studies with all the dideoxy drugs alone and in combination, our group has worked with several CD4 derivatives and a glycosidase inhibitor. Another special focus is our ability to perform Developmental Immunology lab studies measuring lymphocyte functions as well as a variety of immunophenotyping. HLA restricted and natural killer cytotoxicity has been measured during interleukin-2 and gp160 antigen administration to patients with a wide spectrum of HIV disease. Present goals include relating the impact of these new drugs on HIV immunity to changes in virus load. We intend to continue to bring innovative clinical science to bear on infection, but we also must change our patient focus now to bring in more women and minorities as the epidemic changes its pattern making those groups the major targets of infection. Our pharmacology group plans to bring together quantitative viral load markers with careful quantitative pharmacological measurements so as to more effectively individualize therapy to patients. We will also interact more with Stanford's oncologists who are interested in lymphoma to work with them in applying new less toxic anti-idiotype monoclonal technology to non-Hodgkins lymphoma. We will continue our opportunistic infection focus on toxoplasmosis and add MAI and pneumocystis efforts.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (45))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61

Showing the most recent 10 out of 111 publications